Basic Information
| LncRNA/CircRNA Name | n384546 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | papillary thyroid cancer |
| ICD-0-3 | NA |
| Methods | qRT-PCR , Luciferase reporter assay , Western blot , RNA-seq , in vitro knockdown etc. |
| Sample | papillary thyroid cancer tissues ,human normal thyroid epithelial cell line (Nthy-ori 3-1) ,human papillary thyroid carcinoma cell lines (B-CPAP, KTC-1) |
| Expression Pattern | up-regulated |
| Function Description | We identified a novel lncRNA, n384546, which is highly expressed in PTC tissues and cell lines. n384546 expression was associated with clinicopathological features of PTC patients, such as tumor size, lymph node metastasis, and TNM stage. Functionally, knockdown of n384546 inhibited PTC cell proliferation, invasion, and migration both in vitro and in vivo. In addition, we identified miR-145-5p as a key miRNA target of n384546.Furthermore, we found that n384546 could regulate the expression of AKT3 by sponging miR-145-5p. |
| Pubmed ID | 31160577 |
| Year | 2019 |
| Title | A Novel lncRNA n384546 Promotes Thyroid Papillary Cancer Progression and Metastasis by Acting as a Competing Endogenous RNA of miR-145-5p to Regulate AKT3 |
External Links
| Links for n384546 | GenBank HGNC NONCODE |
| Links for papillary thyroid cancer | OMIM COSMIC |